Anti-vimentin antibodies and neuron-specific enolase in children with neurofibromatosis type-1.
OBJECTIVE
The aim of the study was to investigate the relationship of serum levels of neuron-specific enolase, anti-vimentin IgG, and anti-vimentin IgM antibodies in patients with neurofibromatosis type 1 and associated tumors (optic glioma, and plexiform neurofibroma).


METHODS
Measurement of neuron-specific enolase and anti-vimentin antibodies were performed in 131 children and adolescents (67 males, mean age 10 years, range 4-19 years; 64 females, mean age 11 years, range 1-20 years) with three different forms of neurofibromatosis type 1 and in control group of 40 individuals (20 males, mean age 9 years, range 1-19 years and 20 females, mean age 12 years, range 3-18 years).


RESULTS
Anti-vimentin IgG, IgM antibodies and NSE showed similar ability to distinguish between neurofibromatosis type 1 and tumors associated with neurofibromatosis type 1. (AUC=0.57, AUC=0.52 and AUC=0.59 respectively). NSE showed better diagnostic efficiency (AUC=0.68) than the anti-vimentin IgG and anti-vimentin IgM. (AUC=0.63 and AUC=0.56 respectively). Anti-vimentin IgG and IgM antibodies showed higher sensitivity (87.5% and 87.2%) at the cut off value than the NSE (54%). On the contrary, NSE showed higher specificity at the cut off value than both the anti-vimentin IgG and IgM (71% vs. 22.5% and 16% respectively).


CONCLUSIONS
Anti-vimentin IgG and IgM and neuron-specific enolase are relevant markers in investigation of the patients with neurofibromatosis type 1 and associated tumors.
Kotaska
Karel
K
Department of Clinical Biochemistry and Pathobiochemistry, University Hospital Motol, 2nd Medical Faculty, Charles University, Prague, Czech Republic. kotaska@email.cz
Petrak
Borivoj
B
Kukacka
Jiri
J
Kraus
Josef
J
Prusa
Richard
R
D000293:Adolescent; D000328:Adult; D000917:Antibody Formation / Q000276:immunology; D015415:Biomarkers / Q000097:blood; D014408:Biomarkers, Tumor / Q000097:blood; D016543:Central Nervous System Neoplasms / Q000097:blood / Q000150:complications / Q000276:immunology*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007075:Immunoglobulin M / Q000097:blood; D007223:Infant; D008297:Male; D018318:Neurofibroma, Plexiform / Q000097:blood / Q000150:complications / Q000276:immunology*; D009456:Neurofibromatosis 1 / Q000097:blood / Q000150:complications / Q000276:immunology*; D020339:Optic Nerve Glioma / Q000097:blood / Q000150:complications / Q000276:immunology*; D010751:Phosphopyruvate Hydratase / Q000097:blood*; D012680:Sensitivity and Specificity; D012878:Skin Neoplasms / Q000097:blood / Q000150:complications / Q000276:immunology*; D018709:Statistics, Nonparametric; D014746:Vimentin / Q000276:immunology*
D015415:Biomarkers; D014408:Biomarkers, Tumor; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D014746:Vimentin; D010751:Phosphopyruvate Hydratase